Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Mirati Therapeutics Inc    MRTX

MIRATI THERAPEUTICS INC

(MRTX)
  Report  
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
07/15/2019 07/16/2019 07/17/2019 07/18/2019 07/19/2019 Date
105.55(c) 103.45(c) 103.3(c) 105.89(c) 106(c) Last
257 088 398 278 390 023 321 825 236 220 Volume
-0.15% -1.99% -0.14% +2.51% +0.10% Change
More quotes
Financials (CAD)
Sales 2019 1,49 M
EBIT 2019 -182 M
Net income 2019 -176 M
Finance 2019 214 M
Yield 2019 -
Sales 2020 2,71 M
EBIT 2020 -218 M
Net income 2020 -213 M
Finance 2020 174 M
Yield 2020 -
P/E ratio 2019 -28,0x
P/E ratio 2020 -24,7x
EV / Sales2019 3 424x
EV / Sales2020 1 901x
Capitalization 5 324 M
More Financials
Company
Mirati Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing a pipeline of targeted oncology products. The Company's clinical pipeline consists of three product candidates: MGCD265, MGCD516 and mocetinostat. MGCD265 and MGCD516 are... 
More about the company
Surperformance© ratings of Mirati Therapeutics Inc
Trading Rating : Investor Rating :
More Ratings
Latest news on MIRATI THERAPEUTICS INC
07/01MIRATI THERAPEUTICS, INC. : Change in Directors or Principal Officers (form 8-K)
AQ
06/25MIRATI THERAPEUTICS, INC. : Other Events, Financial Statements and Exhibits (for..
AQ
05/16MIRATI THERAPEUTICS : Shares Jump 17% on Rival Amgen's Progress on Potential Can..
DJ
05/15MIRATI THERAPEUTICS, INC. : Change in Directors or Principal Officers, Submissio..
AQ
04/29MIRATI : 1Q Earnings Snapshot
AQ
04/29MIRATI THERAPEUTICS : Management's Discussion and Analysis of Financial Conditio..
AQ
04/29MIRATI THERAPEUTICS, INC. : Results of Operations and Financial Condition, Finan..
AQ
04/25MIRATI THERAPEUTICS, INC. : Change in Directors or Principal Officers (form 8-K)
AQ
02/28MIRATI THERAPEUTICS : Management's Discussion and Analysis of Financial Conditio..
AQ
02/28MIRATI THERAPEUTICS, INC. : Results of Operations and Financial Condition, Finan..
AQ
More news
Sector news : Bio Therapeutic Drugs
07/19Gilead Licenses Respiratory, Herpes Antiviral Research Programs From Novartis
DJ
07/17GILEAD SCIENCES : Chief Scientific Officer John McHutchison to Leave
DJ
07/16As steep patent cliff looms, Shionogi moves to develop its own U.S. sales sta..
RE
07/16GSK's two-drug HIV Dovato treatment meets main goal in study
RE
07/15Gilead invests $5 billion to deepen ties with biotech Galapagos
RE
More sector news : Bio Therapeutic Drugs
Chart MIRATI THERAPEUTICS INC
Duration : Period :
Mirati Therapeutics Inc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MIRATI THERAPEUTICS INC
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 15
Average target price 107,85  CAD
Last Close Price 138,41  CAD
Spread / Highest target -4,63%
Spread / Average Target -22,1%
Spread / Lowest Target -52,3%
EPS Revisions
Managers
NameTitle
Charles M. Baum President, Chief Executive Officer & Director
Rodney W. Lappe Executive Chairman
Jamie A. Donadio Chief Financial Officer & Senior Vice President
Isan Chen EVP, Chief Medical & Development Officer
James G. Christensen Chief Scientific Officer & Executive VP
Sector and Competitors
1st jan.Capitalization (M$)
MIRATI THERAPEUTICS INC149.88%4 077
GILEAD SCIENCES3.98%82 702
VERTEX PHARMACEUTICALS7.47%44 598
REGENERON PHARMACEUTICALS-20.18%32 544
GENMAB14.94%11 908
SAREPTA THERAPEUTICS INC36.77%11 068